Literature DB >> 11734171

[Etiology of community-acquired pneumonia in ambulatory patients. Usefulness of a diagnostic investigation protocol using detection of Streptococcus pneumoniae and Legionella pneumophila antigens in urine samples].

C Mirete Ferrer1, F Gutiérrez Rodero, J C Rodríguez Díaz, G Royo García, C Shum Fhunk, A Martín Hidalgo.   

Abstract

BACKGROUND: To determine the etiology of community-acquired pneumonia (CAP) in ambulatory patients and to assess the efficiency of a diagnostic protocol by using tests to detect bacterial antigens in urine samples. PATIENTS AND
METHOD: One-year prospective study that included blood and sputum cultures, serologic studies, and detection of Legionella pneumophila and Streptococcus pneumoniae urinary antigens.
RESULTS: 49 patients were recruited and an etiological diagnosis was attained in 34 (69%). Microorganisms most frequently isolated were S. pneumoniae (12 cases), Mycoplasma pneumoniae (7), Haemophilus influenzae (4), respiratory viruses (4) and Coxiella burnetii (3 cases).
CONCLUSIONS: By means of a non-invasive protocol with urinary antigen tests, a microbial etiology can be established in two thirds of patients with mild CAP. S. pneumoniae is the main cause of mild CAP.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11734171     DOI: 10.1016/s0025-7753(01)72212-9

Source DB:  PubMed          Journal:  Med Clin (Barc)        ISSN: 0025-7753            Impact factor:   1.725


  3 in total

Review 1.  [Pneumococcal vaccines: problems and solutions].

Authors:  J J Gómez Marco; M Canals Aracil; M C González Martínez; J Antona Casado; A Benito Poveda
Journal:  Aten Primaria       Date:  2003-01       Impact factor: 1.137

2.  [Rapid diagnosis of pneumococcal pneumonia].

Authors:  M A Remacha Esteras; A Esteban Martín; A Morán Blanco; T Remacha Esteras
Journal:  Aten Primaria       Date:  2003       Impact factor: 1.137

Review 3.  Improving outcomes of elderly patients with community-acquired pneumonia.

Authors:  Félix Gutiérrez; Mar Masiá
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.